The global ovarian cancer drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 13.1% over the period through to 2015.
In 2011, the ovarian cancer drugs markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7 million collectively.
The ovarian cancer drugs market is expected to witness three-fold growth by 2020, reaching $2,352 million at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.
Key factors contributing to growth within the industry include the increasing prevalence of ovarian cancer and the trend of the use of combination therapies for the treatment of ovarian cancer. However, patent expiration of key drugs could pose a challenge to the growth of this market.
The current trend occurring in the global ovarian cancer drugs market is the use of combination therapies for the treatment of ovarian cancer.
Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy.
Therefore, combination therapies help in the complete removal of tumours and the destruction of cancerous cells. The combination is chosen according to the size of the tumour and the risk of recurrence.
The patent expiries of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market.
The introduction of new and promising therapies such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350), OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib) are expected to drive the market from 2011-2020.
Key players dominating the global ovarian cancer drugs market include Eli Lilly and Co., GlaxoSmithKline plc, Bristol Myers Squibb Co., and Roche Pharmaceuticals.